Present invention is generally directed to treat glycogen storage disease type Ⅱ by administration or nucleic acid enzyme, the enzyme is to be suitble to the combination of enzyme replacement therapy glycogen storage disease type Ⅱ, in the antisense oligomeric compound of administration, for modulating splicing acid alpha-glucosidase (GAA) gene.
